Alnylam Pharmaceuticals Inc (ALNY)vsNovartis AG ADR (NVS)
ALNY
Alnylam Pharmaceuticals Inc
$248.68
+0.47%
HEALTHCARE · Cap: $34.80B
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1080% more annual revenue ($56.69B vs $4.80B). NVS leads profitability with a 22.5% profit margin vs 16.1%. ALNY appears more attractively valued with a PEG of 0.34. ALNY earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Strong Buy68
out of 100
Grade: B-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.5%
Fair Value
$2584.41
Current Price
$248.68
$2335.73 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 60 in profit
Revenue surging 66.9% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 24.6x book value
Distress zone — elevated risk
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Profitability is solid with margins at 16.1% and operating margin at 17.9%. Revenue growth of 66.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 45.2x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ALNY profiles as a growth stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
ALNY is growing revenue faster at 66.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (68/100 vs 51/100), backed by strong 16.1% margins and 66.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?